The AaPC feeder platform, which is amenable to genetic introduction of TAAs (e. g., ROR1) and molecules that promote T-cell survival (e. g., mIL15), in concert with SB transposition can support the propagation of populations of T cells predicted to have sustained engraftment, i. e., TSCM and CD62L+ TCM populations [12, 48], while enforcing CAR expression on T cells through recursive antigen exposure; therefore, they are attractive platforms for the generation of ROR1-specific T cells for cancer immunotherapy. Here, SELL is linked to cancer.